Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma
Shuchi Gulati, … , Chadi Nabhan, Rana R. McKay
Shuchi Gulati, … , Chadi Nabhan, Rana R. McKay
Published July 15, 2024
Citation Information: J Clin Invest. 2024;134(14):e176230. https://doi.org/10.1172/JCI176230.
View: Text | PDF
Clinical Research and Public Health Oncology Article has an altmetric score of 16

Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma

  • Text
  • PDF
Abstract

BACKGROUND Metastases are the hallmark of lethal cancer, though underlying mechanisms that drive metastatic spread to specific organs remain poorly understood. Renal cell carcinoma (RCC) is known to have distinct sites of metastases, with lung, bone, liver, and lymph nodes being more common than brain, gastrointestinal tract, and endocrine glands. Previous studies have shown varying clinical behavior and prognosis associated with the site of metastatic spread; however, little is known about the molecular underpinnings that contribute to the differential outcomes observed by the site of metastasis.METHODS We analyzed primary renal tumors and tumors derived from metastatic sites to comprehensively characterize genomic and transcriptomic features of tumor cells as well as to evaluate the tumor microenvironment at both sites.RESULTS We included a total of 657 tumor samples (340 from the primary site [kidney] and 317 from various sites of metastasis). We show distinct genomic alterations, transcriptomic signatures, and immune and stromal tumor microenvironments across metastatic sites in a large cohort of patients with RCC.CONCLUSION We demonstrate significant heterogeneity among primary tumors and metastatic sites and elucidate the complex interplay between tumor cells and the extrinsic tumor microenvironment that is vital for developing effective anticancer therapies.

Authors

Shuchi Gulati, Pedro C. Barata, Andrew Elliott, Mehmet Asim Bilen, Earle F. Burgess, Toni K. Choueiri, Sourat Darabi, Nancy Ann Dawson, Benjamin Adam Gartrell, Hans J. Hammers, Elisabeth I. Heath, Daniel Magee, Arpit Rao, Charles J. Ryan, Przemyslaw Twardowski, Shuanzeng Wei, James Brugarolas, Tian Zhang, Matthew R. Zibelman, Chadi Nabhan, Rana R. McKay

×

Figure 6

TME and immunotherapy-associated predictive biomarkers by site of metastases.

Options: View larger image (or click on image) Download as PowerPoint
TME and immunotherapy-associated predictive biomarkers by site of metast...
(A) Heatmap of median cell abundance and gene expression by biopsy site. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 when compared with kidney. Frequency of biomarker-positive samples for (B) PDL1 IHC (SP142 antibody), (C) TMB-High (≥ 10 mut/Mb), and (D) dMMR/MSI-High. NK, natural killer; CTLA4, The cytotoxic T-lymphocyte-associated antigen-4; TIM3, T cell immunoglobulin domain and mucin domain3; LAG3, Lymphocyte-Activation Gene3; PD-1, programmed death-1; PDL1, programmed death ligand-1; PDL2, programmed death ligand-2; GI, gastrointestinal.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 30 X users
7 readers on Mendeley
See more details